David A. Siegel An2 Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 134,700 shares of ANTX stock, worth $142,782. This represents 0.0% of its overall portfolio holdings.
Number of Shares
134,700Holding current value
$142,782% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ANTX
# of Institutions
48Shares Held
19.4MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA5.55MShares$5.88 Million0.18% of portfolio
-
Octagon Capital Advisors LP New York, NY3.22MShares$3.41 Million1.6% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA2.09MShares$2.21 Million0.26% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$1.65 Million0.5% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.55MShares$1.65 Million0.0% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $20.6M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...